Dina Schneider

6PUBLICATIONS
69CO-AUTHORS
Molecular targetsCellular immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

|Jul 03, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.

Djordje Atanackovic, Tim Luetkens, Dina Schneider

|Mar 31, 2025
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.

Nirav N Shah, Alfredo S Colina, Bryon D Johnson

|Apr 12, 2024
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.

Tri Minh Tran, Bal Krishna Chand Thakuri, Saule Nurmukhambetova

|May 23, 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.

Haneen Shalabi, Haiying Qin, Angela Su

|Mar 25, 2021
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.

Dina Schneider, Ying Xiong, Darong Wu

Pageof 1

Frequent Collaborators

2 joint publications

Rimas J Orentas

1 joint publications

Ying Xiong

1 joint publications

Brittany Steimle

1 joint publications

Kim Anthony-Gonda